- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT01121263
Hybrid Revascularization Observational Study
Přehled studie
Postavení
Podmínky
Detailní popis
The increasing prevalence of coronary artery disease (CAD), advances in coronary artery bypass grafting (CABG), percutaneous coronary intervention (PCI), and concomitant medical therapy, and the costs of revascularization have resulted in rising interest regarding the appropriate indications for coronary revascularization. For patients with 3-vessel disease, revascularization by CABG has recently been rated as appropriate while revascularization by PCI has been rated uncertain. Ideally, physicians would like to offer their multi-vessel CAD patients what they truly seek: a solution which provides a safe, minimally invasive treatment that does not compromise long term durability and survival. Integrating the positive features of both PCI and CABG has been the fundamental rationale of "hybrid" coronary revascularization.
Hybrid Coronary Revascularization (HCR) (the intended combination of CABG and PCI) as a scientifically validated approach would have a major healthcare impact. The ability to deliver a new therapy for CAD that provides durability, but without the obligatory trauma and prolonged recovery time characteristic of conventional CABG would be a major advance in the field of cardiovascular medicine. Candidates in whom HCR would be particularly advantageous would be several subgroups of CAD patients that are increasing in numbers: the elderly, patients with a high predicted risk of mortality and/or morbidity for CABG, deconditioned patients or patients with significant disabilities and patients in whom treatment durability is important, but a significantly invasive approach is not an option. Moreover, HCR is likely to bridge the divide in treatment philosophies and approaches that exist between cardiologists and cardiac surgeons. Collaboration rather than competition between these specialties will ultimately benefit patients, hospitals, payers and healthcare providers. The Hybrid Revascularization Observational Study is a multi-center observational study planning grant which will explore target populations for Hybrid Coronary Revascularization (HCR), their outcomes, and variations in specific ways these patients are managed, in order to inform the design of a pivotal comparative effectiveness trial of this emerging therapeutic strategy.
Given the observational nature of the study, the HCR and PCI groups' baseline characteristics and event rates are not directly comparable; rather, the results were intended to inform the design of a larger, randomized pivotal trial. The study was designed in two phases: Cohort 1, which captured demographic, angiographic, and practice patterns data for 6,669 consecutively screened patients; and Cohort 2 which captured demographic, angiographic, practice patterns, and outcome data for 298 patients who underwent either HCR or PCI with DES (90 of whom were also part of Cohort 1).
Typ studie
Zápis (Aktuální)
Kontakty a umístění
Studijní místa
-
-
Georgia
-
Atlanta, Georgia, Spojené státy, 30308
- Emory University
-
-
Maryland
-
Baltimore, Maryland, Spojené státy, 21201
- University of Maryland
-
-
Massachusetts
-
Boston, Massachusetts, Spojené státy, 02115
- Brigham & Women's Hospital
-
-
New York
-
Bronx, New York, Spojené státy, 10461
- Montefiore Medical Center
-
New York, New York, Spojené státy, 10032
- Columbia University Medical Center
-
-
North Carolina
-
Durham, North Carolina, Spojené státy, 27710
- Duke University Medical Center
-
-
Ohio
-
Columbus, Ohio, Spojené státy, 43210
- Ohio State University
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Spojené státy, 19104
- University of Pennsylvania
-
Wynnewood, Pennsylvania, Spojené státy, 19096
- Lankenau Hospital
-
-
Tennessee
-
Nashville, Tennessee, Spojené státy, 37232
- Vanderbilt University
-
-
Virginia
-
Charlottesville, Virginia, Spojené státy, 22908
- University of Virginia Health Systems
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Metoda odběru vzorků
Studijní populace
Cohort 1 (Angiogram Review Group): All consecutive and consenting patients undergoing diagnostic cardiac catheterization in a 3 month period.
Cohort 2 (Therapeutic Intervention Group): All patients (including those from cohort 1) who meet either of the following: (a) undergo HCR with minimally invasive LIMA-LAD CABG (HCR Group) OR (b) meet the proposed anatomic and clinical eligibility criteria defined below and undergo multivessel PCI with DES (PCI Group).
Popis
The following criteria apply to Cohort 2 PCI patients only:
Inclusion Criteria:
- Signed informed consent, release of medical information, and Health Insurance Portability and Accountability Act (HIPAA) documents
- Age 18 years or older
- Clinical indication for revascularization
- LAD and at least one additional vessel coronary disease (> 70% stenosis) confirmed by angiogram
- Clinical characteristics and multi-vessel disease amenable to both PCI with DES and Hybrid as adjudicated by one interventional cardiologist and one cardiac surgeon
- Ability to tolerate and no plans to interrupt double platelet therapy for ≥ 12 months
- Ability to tolerate to single lung ventilation in the judgment of the investigator
- Willing to comply with all protocol required follow-up
Exclusion Criteria:
Previous coronary stent within:
- 1 month prior to enrollment for bare metal stent (BMS) or
- 6 months prior to enrollment for DES
- Evidence of in stent restenosis of a DES or BMS
- Previous cardiac surgery of any kind
- Chronic total occlusion (CTO) in LAD or ≥ 2 CTOs in major coronary territories that are considered targets for revascularization
- Left main disease ≥ 50% stenosis
- Presence of fresh coronary thrombus
- Need for concomitant vascular or other cardiac surgery during the index hospitalization (including, but not limited to, valve surgery, aortic resection, left ventricular aneurysm, carotid endarterectomy or stenting, etc)
- Previous STEMI within 30 days prior to randomization
- Previous stroke within 6 months prior to randomization
- Previous thoracic surgery involving the left pleural space
- Acute decompensated heart failure within 30 days prior to randomization
- Ejection fraction < 30%
- Creatinine clearance ≤ 50 ml/min within 24 hours prior to randomization
- Hemodynamic instability at time of screening
- Body mass index > 40
- Extra-cardiac illness that is expected to limit survival to less than 3 years
- Participation or planned participation in another investigational intervention study within 60 days prior to randomization
- Unable to give informed consent or potential for noncompliance with the study protocol due to psychiatric illness, organic brain disease, dementia, current alcohol abuse, mental retardation, language barrier, or geographical inaccessibility;
- Pregnancy at time of screening or intention to become pregnant
Studijní plán
Jak je studie koncipována?
Detaily designu
- Observační modely: Kohorta
- Časové perspektivy: Budoucí
Kohorty a intervence
Skupina / kohorta |
---|
Angiogram Review Group
All consecutive and consenting patients undergoing diagnostic cardiac catheterization in a 3 month period
|
Therapeutic Intervention Group
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
Major Adverse Cardiac and Cerebrovascular Event (MACCE)
Časové okno: Month 12
|
For the purposes of this study MACCE is defined as a non-weighted composite score comprised of the following components:
|
Month 12
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
Major Adverse Cardiac and Cerebrovascular Event (MACCE)
Časové okno: Occurence of MACCE through the end of study up to two years
|
For the purposes of this study MACCE is defined as a non-weighted composite score comprised of the following components:
|
Occurence of MACCE through the end of study up to two years
|
Spolupracovníci a vyšetřovatelé
Spolupracovníci
Vyšetřovatelé
- Vrchní vyšetřovatel: John Puskas, MD, MSc, FACS, FACC, Emory University
- Vrchní vyšetřovatel: Deborah Ascheim, MD, Icahn School of Medicine at Mount Sinai (Data Coordinating Center)
- Vrchní vyšetřovatel: Joseph J DeRose, MD, FACS, Montefiore Medical Center
- Vrchní vyšetřovatel: Michael Argenziano, MD, FACS, Columbia University
- Vrchní vyšetřovatel: Mathew Williams, MD, Columbia University
- Vrchní vyšetřovatel: John G. Byrne, MD, Vanderbilt University Medical Center
Publikace a užitečné odkazy
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia
Primární dokončení (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Odhad)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Odhad)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
- GCO 09-0657
- 1RC1HL100951 (Grant/smlouva NIH USA)
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .